Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

UNITED THERAPEUTICS (UTHR) EBITDA Margin: 2009-2025

Historic EBITDA Margin for UNITED THERAPEUTICS (UTHR) over the last 17 years, with Sep 2025 value amounting to 48.59%.

  • UNITED THERAPEUTICS's EBITDA Margin rose 278.00% to 48.59% in Q3 2025 from the same period last year, while for Sep 2025 it was 62.63%, marking a year-over-year increase of 1621.00%. This contributed to the annual value of 47.86% for FY2024, which is 305.00% down from last year.
  • Per UNITED THERAPEUTICS's latest filing, its EBITDA Margin stood at 48.59% for Q3 2025, which was up 6.46% from 45.64% recorded in Q2 2025.
  • UNITED THERAPEUTICS's 5-year EBITDA Margin high stood at 62.35% for Q1 2022, and its period low was -4,527.85% during Q4 2024.
  • Over the past 3 years, UNITED THERAPEUTICS's median EBITDA Margin value was 48.19% (recorded in 2025), while the average stood at -367.06%.
  • Per our database at Business Quant, UNITED THERAPEUTICS's EBITDA Margin surged by 7,944bps in 2022 and then plummeted by 457,016bps in 2024.
  • Quarterly analysis of 5 years shows UNITED THERAPEUTICS's EBITDA Margin stood at 40.90% in 2021, then slumped by 517bps to 35.73% in 2022, then soared by 659bps to 42.31% in 2023, then plummeted by 457,016bps to -4,527.85% in 2024, then skyrocketed by 278bps to 48.59% in 2025.
  • Its last three reported values are 48.59% in Q3 2025, 45.64% for Q2 2025, and 48.19% during Q1 2025.